ARDX: 2027 profitability outlook pairs IBSRELA growth with CIC expansion and pipeline investment
Ardelyx, Inc. (ARDX) management anticipates achieving GAAP profitability in 2027, driven by the growth of IBSRELA and strategic investments in payer access. The company expects to release Phase III data for CIC in the second half of 2027, with cash generation allocated towards expanding its pipeline and pursuing business development opportunities. This outlook is based on a transcript from the Jefferies Global Healthcare Conference on November 17, 2026.
Ardelyx (ARDX) Stock May Trade At A Discount On Trial Progress
Ardelyx (ARDX) has seen significant 5-year gains but its current valuation, based on a Price/Sales (P/S) ratio of 1.7x, suggests it may be undervalued compared to the biotech sector and peers. Recent Q3 product revenue growth of 19%, progress in IBSRELA trials, and extended patent coverage contribute to a positive outlook, yet investors remain cautious. Analysts, as reflected in Simply Wall St Narratives, project the stock to be significantly undervalued, contingent on successful management of payer controls and expanded product use.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) for alleged securities fraud. The lawsuit, covering the period from January 13, 2025, to August 6, 2026, claims Ardelyx made misleading statements regarding reimbursement barriers affecting patient access to its drugs, XPHOZAH and IBSRELA, which impacted the company's commercial performance. Shareholders who suffered losses are encouraged to contact SBS by the November 16, 2026 deadline to discuss their rights and potential lead plaintiff appointment.
ARDX Investor Alert: Securities Class Action Against Ardelyx, Inc. (ARDX)
Levi & Korsinsky, LLP has announced a securities class action lawsuit against Ardelyx, Inc. (NASDAQ:ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made materially false and misleading statements regarding the commercial performance and growth prospects of its drugs XPHOZAH and IBSRELA, concealing increasing payer-related access and reimbursement barriers. This led to a significant stock price decline on August 7, 2026, after Ardelyx reduced its IBSRELA revenue guidance and withdrew XPHOZAH's long-term revenue guidance due to market dynamics and utilization management issues.
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made false and misleading statements regarding payer-related access and reimbursement barriers affecting patient access to its products, XPHOZAH and IBSRELA. Investors who suffered losses are encouraged to join the case, with a lead plaintiff deadline of November 16, 2026.
ARDX DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM,
The Rosen Law Firm is reminding investors of Ardelyx, Inc. (NASDAQ: ARDX) who purchased common stock between January 13, 2025, and August 6, 2026, about the important November 16, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that Ardelyx made materially false and misleading statements and concealed facts regarding the commercial performance and growth prospects of its products, XPHOZAH and IBSRELA, particularly concerning increasing payer-related access and reimbursement barriers. Investors are encouraged to secure counsel before the deadline.
Ardelyx Inc Lobbying Profile, 2020
This OpenSecrets profile details Ardelyx Inc.'s lobbying activities and spending for 2026, categorizing it within the Pharmaceuticals/Health Products industry. As of July 23, 2026, Ardelyx spent $1.58 million on federal lobbying. The page provides an overview of their lobbying efforts, including hired firms, lobbyists, issues, agencies, and bills they have influenced.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) for alleged securities fraud. The lawsuit claims Ardelyx made misleading statements regarding reimbursement barriers for its drugs XPHOZAH and IBSRELA, which impacted patient access and the company's commercial performance. Investors who purchased ARDX shares between January 13, 2025, and August 6, 2026, are encouraged to contact SBS by the November 16, 2026 deadline to discuss lead plaintiff opportunities.
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) and certain officers, alleging federal securities law violations. The lawsuit claims that Ardelyx made false and misleading statements regarding increasing payer-related access and reimbursement barriers affecting patient access to XPHOZAH and IBSRELA, which negatively impacted commercial performance. Investors who purchased Ardelyx securities between January 13, 2025, and August 6, 2026, are encouraged to join the case, with a lead plaintiff deadline of November 16, 2026.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX
Pomerantz LLP has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who suffered losses. The lawsuit alleges that Ardelyx and its officers engaged in securities fraud, particularly after the company reduced its 2026 IBSRELA revenue guidance and withdrew its XPHOZAH revenue guidance, leading to a significant drop in stock price. Investors have until November 16, 2026, to apply to be the Lead Plaintiff.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDX
SueWallSt is notifying investors of Ardelyx, Inc. (NASDAQ: ARDX) about a securities class action lawsuit against the company and its Chief Commercial Officer, Eric Foster. The lawsuit alleges Foster made misleading statements regarding the company's patient-access strategy for IBSRELA and XPHOZAH, while payer restrictions were hindering prescriptions. Shareholders who purchased securities between January 13, 2025, and August 6, 2026, and suffered losses are encouraged to come forward as the lead plaintiff deadline is November 16, 2026.
ARDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
Faruqi & Faruqi, LLP reminds investors of the November 16, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit against Ardelyx, Inc. The lawsuit alleges Ardelyx made misleading statements and failed to disclose increasing payer-related access and reimbursement barriers for its drugs, XPHOZAH and IBSRELA. This led to a dramatic stock price decline after the company reduced revenue guidance and withdrew long-term projections on August 6, 2026.
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 16, 2026 - ARDX
Levi & Korsinsky, LLP has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of shareholders who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx officers made misleading statements regarding sales projections for XPHOZAH and IBSRELA while concealing payer access barriers. Investors who suffered losses after an 18% stock drop on August 6, 2026, due to reduced revenue guidance, have until November 16, 2026, to apply for lead plaintiff status.
ARDX Deadline: ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit
Rosen Law Firm is reminding purchasers of Ardelyx, Inc. (NASDAQ: ARDX) common stock between January 13, 2025, and August 6, 2026, of an important November 16, 2026, lead plaintiff deadline for a securities fraud lawsuit. Investors who bought stock during this period may be entitled to compensation without upfront fees. The lawsuit alleges that Ardelyx made misleading statements and concealed material facts regarding the commercial performance and growth prospects of its drugs, XPHOZAH and IBSRELA, impacting patient access and prescription fulfillment.
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) and its officers for alleged federal securities law violations. The lawsuit claims that Ardelyx made false or misleading statements regarding the commercial performance and growth prospects of its drugs, XPHOZAH and IBSRELA, due to increasing payer-related access and reimbursement barriers. Investors who purchased Ardelyx securities between January 13, 2025, and August 6, 2026, are encouraged to join the lawsuit, with a deadline to request lead plaintiff status by November 16, 2026.
Ardelyx, Inc. (NASDAQ:ARDX) SHAREHOLDER ALERT: Investors
The Portnoy Law Firm has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased stock between February 12, 2026, and August 5, 2026. The lawsuit alleges that Ardelyx executives misled investors with overly optimistic revenue projections for IBSRELA and XPHOZAH while concealing increasing payer-related barriers. Investors who suffered losses have until November 16, 2026, to seek appointment as lead plaintiff.
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
Ardelyx Inc. (Nasdaq: ARDX) announced its participation in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT / 6:30 a.m. ET. The company, a commercial-stage biopharmaceutical firm, will provide a live webcast of the chat accessible on its investor relations website, with a replay available afterward. Ardelyx focuses on developing and commercializing innovative medicines, including two approved products in the U.S., IBSRELA® and XPHOZAH®, and has a pipeline for chronic idiopathic constipation (CIC) and other therapeutic areas.
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) and its officers. The lawsuit alleges that Ardelyx made false and misleading statements about payer-related access and reimbursement barriers affecting patient access and commercial performance of its drugs, XPHOZAH and IBSRELA, between January 13, 2025, and August 6, 2026. Investors who suffered losses are encouraged to join the case, with a lead plaintiff deadline of November 16, 2026.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has reminded investors of a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) for alleged securities fraud. The lawsuit claims Ardelyx made misleading statements regarding reimbursement barriers that impacted patient access to its products, XPHOZAH and IBSRELA, leading to delayed new-patient starts and prescription fulfillment. Investors who purchased ARDX shares between January 13, 2025, and August 6, 2026, have an opportunity to lead the lawsuit, with a deadline of November 16, 2026, to contact the firm.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP ("SBS") has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) for alleged securities fraud. Investors who purchased ARDX shares between January 13, 2025, and August 6, 2026, are encouraged to contact the firm by the November 16, 2026, deadline to potentially lead the lawsuit. The complaint alleges that Ardelyx made misleading statements regarding reimbursement barriers and their impact on patient access to its drugs, XPHOZAH and IBSRELA, which affected the Company's commercial performance.
Weekly Recap: Q3 revenue growth and early ACCEL trial enrollment
Ardelyx, Inc. (NASDAQ:ARDX) reported a 15.7% year-over-year revenue increase to $127.7 million in Q3 2026, driven by strong sales of IBSRELA and XPHOZAH, and reaffirmed its 2026 sales guidance. The company also announced the early completion of enrollment for its Phase 3 ACCEL trial of IBSRELA, with topline results anticipated in the second half of 2027.
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Ardelyx, Inc. to Contact the Firm Today!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) and certain officers. The lawsuit alleges that Ardelyx made misleading statements regarding increasing payer-related access and reimbursement barriers affecting patient access to XPHOZAH and IBSRELA, which negatively impacted commercial performance. Investors who purchased Ardelyx securities between January 13, 2025, and August 6, 2026, are encouraged to contact the firm by November 16, 2026, to potentially serve as lead plaintiff.
ARDX DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL,
The Rosen Law Firm is reminding investors who purchased Ardelyx, Inc. (NASDAQ: ARDX) common stock between January 13, 2025, and August 6, 2026, of the November 16, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Ardelyx made misleading statements regarding the commercial performance and growth prospects of its products, XPHOZAH and IBSRELA, concealing issues with payer-related access and reimbursement. Investors who suffered damages are encouraged to contact the firm to join the class action.
Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Ardelyx, Inc. recently reported third-quarter earnings that were in line with expectations, showing the company broke even on statutory EPS with US$128m in revenue. While analysts downgraded revenue forecasts for 2027 to US$610.2m, they became more bullish on earnings, expecting a statutory profit of US$0.24 per share, up from US$0.23. Despite these adjustments, the average price target remained steady at US$12.80, suggesting no significant long-term valuation impact.
ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice - Contact SueWallSt
SueWallSt has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx misrepresented peak sales expectations for its drugs IBSRELA and XPHOZAH while failing to disclose increasing payer utilization-management barriers that restricted patient access and prescription fulfillment. This alleged failure to disclose led to an 18% stock drop after the company reduced its 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance.
ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice - Contact SueWallSt
SueWallSt has issued an investor alert regarding a securities class action lawsuit filed against Ardelyx, Inc. (NASDAQ: ARDX). The lawsuit alleges that Ardelyx misrepresented payer access and reimbursement challenges for its medicines, IBSRELA and XPHOZAH, leading to an approximately 18% stock drop after the company reduced its 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH guidance. Investors who purchased ARDX securities between January 13, 2025, and August 6, 2026, and suffered losses are encouraged to contact SueWallSt to potentially recover their losses.
ARDX Deadline Alert: Levi & Korsinsky Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026
Levi & Korsinsky, LLP reminds investors of Ardelyx, Inc. (ARDX) that a securities class action lawsuit is pending on behalf of shareholders who purchased shares between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made misleading statements about its revenue outlook and growth prospects for IBSRELA and XPHOZAH, while allegedly concealing increasing payer-related access and reimbursement barriers. Investors have until November 16, 2026, to seek lead plaintiff status in the case filed in the United States District Court for the District of Massachusetts.
ARDX Deadline Alert: Levi & Korsinsky Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026
Levi & Korsinsky, LLP has issued a reminder to investors of Ardelyx, Inc. (NASDAQ: ARDX) about a pending securities class action lawsuit, with a lead plaintiff deadline of November 16, 2026. The lawsuit alleges that Ardelyx made misleading statements about its revenue outlook and growth prospects for IBSRELA and XPHOZAH, while failing to disclose increasing payer-related access and reimbursement barriers. This allegedly led to a significant stock decline when updated guidance was finally disclosed.
Ardelyx, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:ARDX) 2026-11-03
Ardelyx, Inc. (NASDAQ:ARDX) published its slide deck for the 2026 Q3 earnings call. The company reported an EPS of $0.00, beating estimates by $0.02, while revenue of $127.66 million, a 15.70% year-over-year increase, missed expectations by $349.63K.
ARDX: Revenue grew 19% as IBSRELA led; guidance was reaffirmed and profitability remains targeted for 2027
Ardelyx, Inc. (ARDX) reported a 19% year-over-year increase in Q3 product revenue, reaching $125.5M, primarily driven by IBSRELA. The company's net loss narrowed to $0.7M, and it reaffirmed its FY 2026 product and expense guidance, maintaining its target for profitability in 2027. This information is based on Ardelyx's Q3 2026 audio transcript from November 3, 2026.
Ardelyx Q3 2026 Earnings Call Transcript
Ardelyx reported strong financial results for Q3 2026, with total revenue increasing 19% year-over-year to $125.5 million, primarily driven by IBSRELA and XPHOZAH. The company is accelerating IBSRELA's growth through a direct-to-consumer ad campaign and efforts to reduce payer friction, while XPHOZAH continues its momentum in the CKD dialysis market. Ardelyx also announced the full enrollment of its EXCEL Phase 3 trial for IBSRELA in chronic idiopathic constipation, with results expected in the second half of 2027, and reaffirmed its full-year 2026 guidance, maintaining its path to profitability by 2027.
Earnings call transcript: Ardelyx tops growth goals in Q3 2026 as stock jumps
Ardelyx reported strong Q3 2026 results, with product revenue up 19% year-over-year to $125.5 million, driven by IBSRELA and XPHOZAH. Despite a slight revenue miss, the company's net loss narrowed to $700,000, and its shares jumped 9.57% in after-hours trading, reflecting investor confidence in its path to profitability in 2027 and the strong demand for its key products. Ardelyx reaffirmed its full-year 2026 guidance and announced early enrollment completion for its IBSRELA Phase III CIC trial.
A constipation drug trial enrolled all its patients ahead of schedule. Results are expected in the second half of 2027.
Ardelyx (NASDAQ: ARDX) has completed enrollment for its Phase 3 ACCEL clinical trial ahead of schedule, evaluating IBSRELA® (tenapanor) for chronic idiopathic constipation (CIC) in adults. Topline data from the multicenter, randomized, double-blind, placebo-controlled trial are anticipated in the second half of 2027. This trial aims to assess IBSRELA's safety and efficacy for a broader patient population, as the drug is currently approved for irritable bowel syndrome with constipation (IBS-C) but not CIC.
ARDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ:ARDX) and some of its officers. The lawsuit, filed on behalf of investors who purchased Ardelyx securities between January 13, 2025, and August 6, 2026, alleges that the company made misleading statements regarding patient access and reimbursement barriers affecting its products, XPHOZAH and IBSRELA. Investors who suffered losses have until November 16, 2026, to request to be appointed as lead plaintiff.
BTIG Remains a Buy on Ardelyx (ARDX)
BTIG analyst Julian Harrison reiterated a Buy rating on Ardelyx (ARDX) with a $14.00 price target, following the company's Q2 earnings report which showed increased revenue and a reduced net loss year-over-year. Despite the positive analyst sentiment, corporate insider activity indicates a negative sentiment due to increased selling of shares by insiders. Separately, Ardelyx is facing a securities lawsuit related to alleged hidden payer hurdles and misleading drug revenue guidance for IBSRELA.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has reminded investors of a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) for alleged securities fraud. The lawsuit claims Ardelyx made misleading statements regarding reimbursement barriers that impacted patient access to its drugs, XPHOZAH and IBSRELA, affecting the company's commercial performance. Investors who purchased ARDX shares between January 13, 2025, and August 6, 2026, have until November 16, 2026, to contact SBS regarding potential lead plaintiff appointments.
ARDX Q3'26 Earnings: EPS estimate is (0.02) USD
Ardelyx, Inc. (ARDX) is projected to announce its Q3'26 earnings after market close on November 3rd, with an estimated EPS of (0.02) USD and revenue of 127.99 million USD. The article provides a detailed comparison of reported versus estimated revenue and EPS for several recent quarters, highlighting past surprises. Investors can find more details on ARDX's financial performance on TradingView's ARDX Financials page.
Ardelyx Inc (41X.SG) Seasonal returns chart
The article provides a seasonal returns chart for Ardelyx Inc (41X.SG), showing its average monthly price return from 2017 to 2026. It also notes the company's Q3 2026 earnings call scheduled for November 2nd at 10:30 pm GMT+1, and lists its current stock price and performance.
ARDX DEADLINE: SueWallSt Reminds Ardelyx, Inc. Investors of Upcoming Securities Class Action Deadline
SueWallSt reminds investors of the upcoming November 16, 2026 deadline to file motions for lead plaintiff in a securities class action lawsuit against Ardelyx, Inc. The lawsuit alleges that Ardelyx made misleading statements about its payer utilization management and prescription pull-through, which negatively impacted new-patient starts for IBSRELA, despite reaffirming high sales guidance. Ardelyx shares fell approximately 18% after the company reduced its full-year 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH guidance.
Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors of Ardelyx, Inc. (NASDAQ: ARDX) who purchased common stock between January 13, 2025, and August 6, 2026, about the upcoming November 16, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Ardelyx made misleading statements regarding the commercial performance and growth prospects of its products, XPHOZAH and IBSRELA, concealing increasing payer-related access and reimbursement barriers. Investors who suffered losses exceeding $100,000 are encouraged to join the class action to potentially recover compensation.
Ardelyx faces growth challenges with slowed revenue and reimbursement issues, maintaining Hold rating.
Ardelyx, Inc. is maintaining a Hold rating due to slowed revenue growth and ongoing challenges with Medicare reimbursement for its XPHOZAH product, despite nearly $500 million in annual revenue. The company lowered its 2026 revenue guidance for IBSRELA and faces concerns regarding its heavy reliance on tenapanor and lack of pipeline diversification. While a CIC opportunity could boost growth, execution and payer access risks remain significant short-term challenges.
Ardelyx, Inc. (ARDX) Seasonal returns chart
This article provides a seasonality chart for Ardelyx, Inc. (ARDX), showing average monthly price returns from 2016 to 2026. It also lists current stock information, including the real-time Nasdaq price and after-hours trading, and mentions the upcoming Q3 2026 earnings call.
ARDX DEADLINE: SueWallSt Reminds Ardelyx, Inc. Investors of Upcoming Securities Class Action Deadline
SueWallSt has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made misleading statements regarding payer utilization management and prescription pull-through, which affected IBSRELA sales and led to reduced revenue guidance. Investors who suffered losses after the company's stock dropped approximately 18% on August 7, 2026, have until November 16, 2026, to file motions for lead plaintiff.
Ardelyx, Inc. Class Action Reminder – Robbins LLP
Robbins LLP is reminding investors of a class action lawsuit filed against Ardelyx, Inc. (NASDAQ: ARDX). The lawsuit alleges that Ardelyx misled investors about the commercial performance and growth prospects of its drug products, IBSRELA and XPHOZAH, by concealing increasing payer-related access and reimbursement barriers. This allegedly caused a significant drop in Ardelyx's stock price after the company reduced its revenue guidance.
Earnings Preview: Ardelyx to Report Financial Results Post-market on November 03
Ardelyx is scheduled to report its financial results after the market closes on November 3rd. Investors will be watching for insights into the company's performance and future outlook. This earnings report will provide crucial information regarding Ardelyx's financial health and operational progress.
Ardelyx (ARDX) Could Be 76% Undervalued As Kidney Week Puts Focus Back On Valuation
Ardelyx (ARDX) is presenting at Kidney Week 2026, bringing renewed focus to its valuation after a volatile year for its stock. Despite a significant year-to-date share price decline, a widely followed narrative suggests the company is 76% undervalued, with a fair value of $12.90 compared to its current $3.10 share price. This valuation is based on assumptions of strong revenue growth and future profit margins, driven by an expanding market for its kidney and gastrointestinal disorder treatments.
ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Levi & Korsinsky, LLP has alerted investors in Ardelyx, Inc. (NASDAQ: ARDX) about a pending securities class action lawsuit. The lawsuit is on behalf of shareholders who purchased or acquired common stock between January 13, 2025, and August 6, 2026, alleging the company made misleading statements regarding its revenue outlook and growth prospects, particularly concerning payer access barriers. The stock price declined sharply after Ardelyx reduced 2026 IBSRELA guidance and withdrew long-term XPHOZAH guidance.
Kaplan Fox Urges Ardelyx, Inc. (NASDAQ: ARDX) Investors to Contact the Firm Before the Deadline on November 16, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased stock between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx disseminated false and misleading statements regarding its commercial performance and growth prospects for IBSRELA and XPHOZAH, particularly concerning increasing payer-related access and reimbursement barriers. Investors are urged to contact Kaplan Fox before the November 16, 2026 deadline to learn more about becoming a lead plaintiff.
Kaplan Fox Urges Ardelyx, Inc. (NASDAQ: ARDX) Investors to Contact the Firm Before the Deadline on November 16, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased common stock between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made false and misleading statements regarding its commercial performance and growth prospects for IBSRELA and XPHOZAH, particularly concerning increased payer utilization-management processes that restricted patient access and slowed new-patient starts. Investors are encouraged to contact Kaplan Fox before the November 16, 2026 deadline to learn more about becoming a lead plaintiff.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding purchasers of Ardelyx, Inc. (NASDAQ: ARDX) common stock between January 13, 2025, and August 6, 2026, of an important November 16, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Ardelyx made materially false and misleading statements and concealed facts regarding the commercial performance and growth prospects of XPHOZAH and IBSRELA, specifically concerning payer access and reimbursement barriers. Investors who purchased during the Class Period may be entitled to compensation and are encouraged to contact Rosen Law Firm for information on joining the class action.